What is the recommended eltrombopag dosing and monitoring strategy for a patient with myelodysplastic syndrome and thrombocytopenia?

Eltrombopag in MDS with Thrombocytopenia: Critical Safety Warning

Do NOT use eltrombopag in combination with azacitidine in MDS patients with thrombocytopenia—this combination significantly increases mortality (42% increased risk of death) and progression to AML (166% increased risk). 1

When Eltrombopag May Be Considered (Monotherapy Only)

Eltrombopag monotherapy can be considered as a "useful in certain circumstances" option for select MDS patients with clinically significant thrombocytopenia, particularly those who are:

• Low or intermediate-1 risk (IPSS)
• Not candidates for or have failed other therapies
• Have severe thrombocytopenia (platelets <30 × 10⁹/L) 2

Patient Selection Criteria

The following characteristics predict better response to eltrombopag monotherapy:

• Presence of PNH clone
• Bone marrow hypocellularity
• Isolated thrombocytopenia or thrombocytopenia with other cytopenias
• Elevated plasma thrombopoietin levels 3

Dosing Strategy

Initial Dosing

• Start at 50 mg once daily (25 mg for East Asian ancestry or hepatic impairment) 1
• Escalate by 25-50 mg increments every 2 weeks based on platelet response
• Maximum dose: 300 mg daily (though 150 mg is often sufficient) 3, 4

Administration Requirements

• Take on an empty stomach: 1 hour before or 2 hours after food
• Avoid within 4 hours of polyvalent cations (calcium, iron, magnesium, aluminum, zinc)
• Separate from dairy products and calcium-fortified foods by at least 4 hours 1

Monitoring Protocol

Baseline Assessment

• Complete blood count with differential
• Comprehensive metabolic panel including ALT, AST, total and direct bilirubin
• Bone marrow examination with cytogenetics and blast percentage
• Peripheral blood blast count 1

During Dose Escalation (First 16-20 weeks)

• CBC weekly to assess platelet response
• Liver function tests every 2 weeks (ALT, AST, bilirubin)
• Peripheral blood smear for blast count monitoring 1

After Stable Dose Achieved

• CBC weekly initially, then can extend to every 2-4 weeks if stable
• Liver function tests monthly
• Bone marrow examination every 3-6 months to monitor blast percentage and assess for increased reticulin fibrosis 1

Response Assessment

Expected Timeline

• Platelet response typically occurs within 2-4 weeks of reaching therapeutic dose
• Assess formal response at 16-20 weeks 5, 6

Response Definitions

• Complete response: Platelets ≥100 × 10⁹/L
• Partial response: Platelets 30-100 × 10⁹/L or 50% increase from baseline
• Target platelet count: 50-150 × 10⁹/L (do NOT attempt to normalize counts) 1

Response Rates in MDS

• Overall response rate: 24-47% depending on patient selection 5, 6, 3, 4
• Uni-lineage or bi-lineage hematologic improvement possible in some patients 3
• Median duration of response: 40 weeks to >1 year in responders 5, 7

Critical Safety Considerations

Hepatotoxicity

Discontinue immediately if:

• ALT ≥3× ULN (normal baseline) or ≥3× baseline (elevated baseline) or >5× ULN (whichever is lower) AND any of:
  • Progressive increase
  • Persistent ≥4 weeks
  • Accompanied by increased direct bilirubin
  • Clinical symptoms of liver injury 1

Thrombotic Risk

• Risk increases with platelet counts >200 × 10⁹/L
• Particular concern in patients with chronic liver disease (portal vein thrombosis risk)
• Monitor for signs/symptoms of thromboembolism
• Consider prophylactic anticoagulation in high-risk patients 1

Disease Progression Monitoring

• Monitor peripheral and bone marrow blasts regularly
• Approximately 12-17% risk of AML progression (similar to placebo in most studies, but significantly higher when combined with azacitidine) 1, 5, 8
• One case report of reversible peripheral blast increase 7

Bone Marrow Fibrosis

• Increased reticulin reported in some patients
• Requires periodic bone marrow monitoring
• Usually reversible upon discontinuation 9

Dose Modifications

For Thrombocytopenia

• If platelets drop <30 × 10⁹/L after initial response: hold dose temporarily
• Resume at same or reduced dose when platelets recover

For Thrombocytosis

• Platelets 200-400 × 10⁹/L: Reduce dose by 25-50 mg
• Platelets >400 × 10⁹/L: Hold until <150 × 10⁹/L, then resume at reduced dose 1

For Hepatotoxicity

• Grade 1-2 elevation: Continue with close monitoring
• Grade 3-4: Discontinue (see above criteria)

Discontinuation Strategy

When to Consider Stopping

• After achieving stable response for ≥6 months with low-dose therapy (25-50 mg)
• No bleeding events during treatment
• Stable disease without progression 10

Tapering Protocol

• Reduce by 25 mg every 2 weeks
• At 25 mg daily: switch to every other day for 2 weeks
• Then every 4 days before complete discontinuation 10

Post-Discontinuation

• Monitor CBC weekly for 4 weeks, then monthly
• Approximately 25% may lose response after discontinuation
• Can successfully re-initiate if needed 5, 7

Common Pitfalls

1. Using with azacitidine: Absolutely contraindicated based on increased mortality and AML progression 1

2. Inadequate food/drug separation: Polyvalent cations dramatically reduce absorption—strict 4-hour separation required 1

3. Over-treating platelet counts: Target is 50-150 × 10⁹/L, NOT normalization—higher counts increase thrombotic risk 1

4. Insufficient monitoring: Hepatotoxicity can be severe and requires vigilant LFT monitoring every 2 weeks during dose escalation 1

5. Ignoring blast counts: Regular peripheral blood and bone marrow blast monitoring essential to detect progression 1

6. Using in higher-risk MDS: Evidence supports use primarily in low/intermediate-1 risk disease; higher-risk patients had poor outcomes 8